TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04721067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHUTi
Description: SHUTi is the empirically supported, internet CBT-I that is fully accessible via tablets and smartphones. It uses a self-guided, fully automated, interactive, multimedia format to deliver six 45-minute sessions, the structure and content of which mirror traditional face-to-face CBT-I. Session content includes sleep restriction, stimulus control, sleep hygiene, cognitive restructuring, and relapse prevention. SHUTi is enhanced through a variety of interactive features, including personalized goal setting, graphical feedback based on inputted symptoms, animations and illustrations to enhance comprehension, quizzes to test user knowledge, patient vignettes, and video-based expert explanation. Across sessions, patients also receive tailored sleep recommendations and feedback based on the sleep diary data they enter into the program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education/Hygiene
Description: A research assistant (RA) will deliver the active control procedures. During the first 4 weeks, the RA will have two calls with each control participant - one 45-minute call on insomnia education (including their HIV provider's role in its management) and one 45-minute call on sleep hygiene practices. To end the first call, the RA will email or mail a list of local behavioral health services to patients and will encourage them to follow-up with their HIV provider. We will then notify the HIV provider, which will encourage them to address their patient's insomnia and provide the same list of local services.
Study: NCT05692024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend capsule.
Description: Each coffee capsule will contain 400 mg Nestlé NESCAFÉ® TASTER'S CHOICE® House Blend.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo capsule will contain 400 mg of microcrystalline cellulose with flavor and food-coloring substances.
Study: NCT05161429

Intervention type: DRUG
Intervention: DPP4
Description: Dipeptidyl peptidase-4 inhibitors (DPP4) including alogliptin, linagliptin, sitagliptin, and saxagliptin

Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: Glucagon-like peptide-1 receptor agonists (GLP1-RA) including dulaglutide, exenatide, liraglutide and semaglutide

Intervention type: DRUG
Intervention: Basal Insulin
Description: degludec, detemir, glargine and NPH

Intervention type: DRUG
Intervention: SLGT2
Description: Sodium-glucose cotransporter-2 inhibitors (SLGT2) including canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin

Intervention type: DRUG
Intervention: SU
Description: Sulfonylurea (SU) including glimepiride, glipizide, and glyburide
Study: NCT04747743

Intervention type: OTHER
Intervention: a self structured questionnaire
Description: A self structured questionnaire to assess knowledge of skeletal muscle use in dental practice
Study: NCT05517330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: 30mg PO QD
Study: NCT05582161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAOIB
Description: The DAOIB dose will be adjusted every 8 weeks according to clinical evaluation.
Study: NCT05088954

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transforaminal epidural steroid injection
Description: In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transforaminal epidural steroid injection
Description: In the transforaminal approach, a small amount of drug is injected into the epidural space, and in previous studies, reduction in pain and improvement in functionality were found in patients with lumbar radicular pain in the short and medium term.
Study: NCT04700852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Puressentiel protective nasal spray
Description: provocative nasal test with grass pollen and nasal lavage
Study: NCT06379867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK3486
Description: 0.4 mg/kg, IV bolus administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV bolus administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 0.4 g, Oral administration with 240 mL
Study: NCT04912791

Intervention type: PROCEDURE
Intervention: Obstetric anesthesia and analgesia
Description: All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
Study: NCT06717542

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: RT-PCR
Description: Custom RT-PCR analyses will be performed manually for the transcripts (mRNA) of the ERG, Nestin, VEGFR and other genes, at the Pathology Anatomy lab hall. 18 (Prof. D'Errico). Total RNA will be extracted from the paraffin blocks with the RecoverAll™ Total Nucleic Acid Isolation kit (Invitrogen). Reverse Transcriptase will be performed with the High Capacity Reverse Transcription kit (Life Technologies), using the specific primers. Real-Time PCR will be performed with the CFX Connect Real-Time PCR Identification System (BioRad).
Study: NCT06032611

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: COGNUM_ALZVR
Description: Participants will complete a battery of tests/quizzes:~* cognitive tests~* medical questionnaire~* lifestyle/fragility questionnaire~* digital clock test~* fine motor skills tests They will also wear a connected watch for 7 days.
Study: NCT05618444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Management (AM)
Description: A tele-management intervention that will deliver two-way messages to participants via a bot - a computer program that simulates human activity. Programmed AM messages will address evidence based intervention components for positive airway pressure (PAP) adherence, including PAP use awareness (tele-monitoring), support and troubleshooting, education, and brief motivational messaging.
Study: NCT05910567

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Focused Assessment with Sonography for Trauma (FAST) Examination
Description: A bedside Focused Assessment with Sonography for Trauma (FAST) Examination will be conducted on those participants who are randomized to the FAST arm.

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention: Standard of Care - Without the FAST Examination
Description: Participants randomized to usual care will be evaluated per the standard operating procedures of the institution/site for the condition under study without the FAST exam.
Study: NCT05457595

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion radiation therapy
Description: CIRT: Planning Target Volume (PTV) will be delivered a total dose of 48-52.8 GyRBE in 12 fractions, 4 fractions per week. Treatment duration 3 weeks.~Treatment lasting more than 5 weeks or cases of treatment with less than 6 fractions in 14 consecutive days will not be accepted.
Study: NCT04388163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentian Violet
Description: Gentian violet is a topical antiseptic used to treat many cutaneous yeast infections. It also has a role in improving wound healing in sites of active ulceration.
Study: NCT05459298

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo is normal saline, given in the first 28 days after birth, prepared to have the same volume and appearance as vitamin D, which is a clear odorless solution.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin D supplementation with feedings in the first 28 days after birth
Description: 800 IU/day Vitamin D supplementation until 400 IU/day are provided as part of usual care (started when infants receive full feedings of about 120-160 mL/kg/day). At that point the intervention becomes a supplement of 400 IU/day above that given with usual care. In this way all infants in the intervention group receive 800 IU/day of vitamin D total supplementation in the first 28 days after birth with feedings.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices. When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Care will be unaffected and provided based on the judgment of the attending neonatal faculty and NICU policies and routine practices. When the infant receives about 120 to 160 mL/kg/day of fortified milk at 24 kcal/ounce, the infant will receive supplementation with 400 IU/day of vitamin D as usual care.
Study: NCT05986929

Intervention type: OTHER
Intervention: focus group
Description: Two semi-structured group interviews, lasting 30-60 minutes, on facilitators and barriers to poster use by staff members (N=6-8).

Intervention type: OTHER
Intervention: electronic survey
Description: An electronic survey of 15 closed questions on the acceptability of the magnetic posters (N=100).
Study: NCT05377060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plasma p-tau risk disclosure
Description: Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, MMSE score, and plasma p-tau results.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard risk disclosure
Description: Participants will receive an estimated risk for converting to dementia in the next four years based on age, sex, and MMSE score.
Study: NCT04696146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berinert
Description: Intrarenal dose of 500 U of Berinert

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline placebo
Study: NCT06270407

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid 100 MG/ML
Description: If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using tranexamic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%sodium chloride
Description: If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
Study: NCT06093087

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SAIF
Description: The patient was placed in a prone position under general anesthesia. Using a C-arm X-ray machine and a positioning plate for navigation, the target position on the vertebral body was located one the surface of the body. The puncture needle core was withdrawn after puncturing, and a guide needle was inserted. After removing the puncture needle sleeve, a hollow bone cement screw was screwed into the anterior column of the vertebral body through the guide needle. Subsequently, bone cement was injected into the appropriate position through the bone cement screw to restore the vertebral height

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: BKP
Description: The patient was placed in a prone position after general anesthesia. Using a C-arm X-ray machine and a positioning plate for guidance, the target position on the vertebral body was located from the surface of the body. A puncture needle sleeve was inserted into the vertebral body. A PKP balloon was then inserted to perform vertebral restoration. After removing the balloon, an appropriate amount of bone cement was injected to ensure even distribution within the vertebral body. Vertebral height augmentation and restoration will then be achieved.
Study: NCT02575508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pan FGFR Kinase Inhibitor BGJ398
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT05678231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zero Degree Knee Positioner
Description: The Zero Degree Knee (ZDK) positioning device is a knee extension pillow designed to simplify knee extension exercise following TKA surgery.
Study: NCT05688969

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: early versus late biopsy
Description: early (3-6 weeks) versus late (6-8 months) biopsy
Study: NCT06455176

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar cleft Grafting from the symphysis
Description: grafting using particulate bone from the symphysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar cleft Grafting from the iliac cancellous bone
Description: grafting using iliac cancellous bone
Study: NCT05916040

Intervention type: DEVICE
Intervention: Radiotherapy with MRIdian with simultaneous integrated boost
Description: radiotherapy during 5 days given in 5 weekdays with simultaneous integrated boost

Intervention type: OTHER
Intervention: Questionnaires before, during and after radiotherapy
Description: Questionnaires consisting of 3 quality of life scales and 1 mental state scale:~* EORTC QLQ-C30~* EORTC QLQ-CR29~* Low Anterior Resection Syndrome Score (LARS) questionnaire~* Hospital Anxiety and Depression Scale (HADS) questionnaire
Study: NCT04551495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entrectinib
Description: Entrectinib is administered orally at a dose of 600 mg once a day from days 1 to 28 of a 28-day cycle for four cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is administered orally at a dose of 2.5 mg once a day from days 1 to day 28 of a 28 day cycle for four cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: Goserelin is administered subcutaneously at a dose of 3.6 mg at the beginning of each cycle for 4 monthly cycles to pre-menopausal women
Study: NCT04795531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo insulin icodec
Description: You will get a pen for weekly injection and one for daily injection. One will be insulin degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Description: You will get a pen for weekly injection and one for daily injection. One will be degludec 100 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections
Study: NCT06226922

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT06118502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Switching to a different medication
Description: Participants will receive four weeks of the other FDA approved option, either varenicline or combination NRT, with instructions to try to quit again at week 4.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continued use of the same medication
Description: Participants will receive four additional weeks of the same medication (varenicline or NRT) with instructions to try to quit again at week 4.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continued use of the same medication
Description: Participants will receive four additional weeks of the same medication (varenicline or NRT) with instructions to try to quit again at week 4.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Switching to a harm reduction tobacco product
Description: Participants will receive four weeks of e-cigarette products with instructions to switch completely at Week 8
Study: NCT04888676

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Class II Restoration
Description: A Class II cavity will be prepared after local anesthesia has been given as required.Rubber dam isolation will be done.Sectional matricing and wedging will be done. Followed by, placement of restorative material according to the randomization sequence.followed by filling of cavity in increments of 3-4mm

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Class II Restoration
Description: A Class II cavity will be prepared after local anesthesia has been given as required.Rubber dam isolation will be done.Sectional matricing and wedging will be done. Followed by, placement of restorative material according to the randomization sequence.followed by filling of cavity in increments of 3-4mm
Study: NCT04795531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo insulin degludec
Description: You will get a pen for weekly injection and one for daily injection. One will be icodec 700 units/mL and the other will be placebo.~Subcutaneously (under the skin) injections
Study: NCT05146349

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Minnesota RETAIN
Description: RETAIN projects include a combination of medical provider services, stay-at-work/return-to-work (SAW/RTW) coordination services, and other SAW/RTW services. The evaluation compares the treatment group that is eligible to receive the full set of RETAIN intervention activities and an control group that is not.
Study: NCT05450328

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined Epoprostenol Sodium & Milrinone
Description: One syringe containing 4mg of milrinone (1mg/mL, 4mL) and one syringe containing 60 mcg of epoprostenol (15 mcg/mL, 4mL).~The drugs will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions.
Study: NCT05544721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 0.5% 3-4 mL per level, with levels T1 and T2 will be used as the block injectate
Study: NCT05450328

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The control group will receive two syringes of 4mL of Normal Saline, before CPB start.~The placebo will be administered via an ultrasonic nebulizer (Aeroneb Professional Nebulizer System, Aerogen Ltd, Galway, Ireland, registration number: 66728) over a period of 20 minutes. This type of nebulizer is used routinely at the Montreal Heart Institute and can hold a maximum of 8 mL of solutions.
Study: NCT06304649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cast or brace alternative
Description: Waterproof alternative to a cast or brace for broken bones
Study: NCT04828798

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation of the VIM Thalamic nuclei
Description: Deep brain stimulation of the thalamus, in a directional and nondirectional manner

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation of the VIM Thalamic nuclei
Description: Deep brain stimulation of the thalamus, in a directional and nondirectional manner
Study: NCT06451497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZM008
Description: Intravenous delivery
Study: NCT05705518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systane Complete PF
Description: 3 month use, 4 times daily, of Systane Complete PF, a lipid-based, preservative-free artificial tear product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Refresh Relieva PF
Description: 3 month use, 4 times daily, of Refresh Relieva PF, a non-lipid-based, preservative-free artificial tear product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Optive Mega-3 PF
Description: 3 month use, 4 times daily, of Refresh Optive Mega-3 PF, a lipid-based, preservative-free artificial tear product

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CVS Health Lubricant Eye Drop (PG 0.6%)
Description: 3 month use, 4 times daily, of CVS Health Lubricant Eye Drop (PG 0.6%), a lipid-based, preserved artificial tear product
Study: NCT04990557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 and ACE2 Knockout T Cells
Description: Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
Study: NCT05814328

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transitional Care
Description: Targeted inhospital intervention of GMT for patient aged 75 ans more with TRST score ≥2 with a follow-up after ED discharge. Transitional Care is defined by a geriatric team having intervention strategies linked to community care: home visits with community professionals and/or multidisciplinary clinical meetings and/or shared professionals and/or shared information systems.
Study: NCT04990557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 and ACE2 Knockout T Cells
Description: Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 and ACE2 Knockout T Cells
Description: Autologous lymphocytes are collected and both PDCD1 and ACE2 gene knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
Study: NCT05647460

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: computer guided screw holes locating guide and custom-made plates
Description: Virtual planning and guide fabrication for the study group:~* Preoperative CT.~* Virtual reduction of broken segments on software.~* Gain occlusion.~* Design surgical screw holes locating guide.~* Design the custom-made plates.~* Print the screw holes locating guide and the custom-made plate.~* Surgical guiding tools: screw holes locating guide and custom-made plates.~Put the specific screw holes locating device in place and drill the screw holes, remove the screw holes locating device and mobilize the segments then apply the custom-made plates and fix it with screw for passive reduction of the segments. Then suture the mentalis muscle then the mucosa.